Clinical Trial Update: Efficacy, Safety and Immunogenicity of the Proposed Biosimilar Vedolizumab PB016 in Comparison With Entyvio® [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy, safety, and immunogenicity of the proposed vedolizumab biosimilar PB016 compared with Entyvio. The study targets patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Entyvio (vedolizumab)
• Vedolizumab PB016 (vedolizumab)

Snippet

Sponsor: Polpharma Biologics S.A. | Conditions: Ulcerative Colitis | Phase 3 | Status: ACTIVE_NOT_RECRUITING